Royalty Pharma Plc Class A (RPRX)

Over the past six months, Royalty Pharma Plc's stock price has increased significantly. The company reported Q4 and full year 2024 results, Q1 2025 earnings, and robust Q2 2025 results. A new share repurchase program of up to $3.0 billion was authorized in January 2025. Royalty Pharma was downgraded to "Hold" by TD Cowen. A 14.244 million share block trade occurred around November 8, 2025, priced at $40.00. The Annual General Meeting was held on June 6, 2024. The stock reached its 52-week high of $41.24 and a 52-week low of $24.05.

Information detailing the demand seasonality for Royalty Pharma Plc's products and services is not explicitly available. Demand for the underlying biopharmaceutical products is typically driven by medical need and patient populations, which generally do not exhibit strong seasonality unless tied to specific seasonal illnesses or healthcare cycles.

Royalty Pharma Plc is a funder and buyer of biopharmaceutical royalties, acquiring rights to royalty payments from approved and late-stage biopharmaceutical products. The company collaborates with innovators, funding innovation directly and indirectly. Its portfolio includes royalties on over 35 commercial products, including Imbruvica, Xtandi, Tysabri, Spinraza, Gilead's HIV franchise and Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Symdeko, Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Servier's Voranigo, and Pfizer's Nurtec ODT.

Royalty Pharma Plc is headquartered in New York, NY, USA, and serves global markets. Its shares are listed on Nasdaq (RPRX) and traded on several international exchanges, including the Munich, Frankfurt, Dusseldorf, Stuttgart, Berlin, Mexico, and Berne Stock Exchanges.

Royalty Pharma has a strong brand reputation as a leading biopharmaceutical company focused on acquiring and investing in royalty streams of innovative medicines. The company aims to generate long-term returns for shareholders by investing in established and developing biopharmaceutical products. MarketBeat analysis indicates that Royalty Pharma scored higher than 88% of companies evaluated in the medical sector.

The ownership structure of Royalty Pharma is a mix of institutional, insider, and retail investors. Approximately 54.35% of the stock is held by institutions, 18.90% by insiders, and 25.83% by retail investors. Major institutional owners include Morgan Stanley, Fmr Llc, Capital International Investors, BlackRock, Inc., Baillie Gifford & Co, Swedbank AB, Adage Capital Partners Gp, L.l.c., Vanguard Group Inc, and State Street Corp. VANGUARD INDEX FUNDS owns the most shares of Royalty Pharma Plc.